Passage Bio, Inc. (PASG)
4.61
+0.17
(+3.83%)
USD |
NASDAQ |
Sep 02, 16:00
4.40
-0.21
(-4.56%)
Pre-Market: 08:52
Passage Bio Research and Development Expense (Annual) : 23.28M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 23.28M |
| December 31, 2024 | 40.18M |
| December 31, 2023 | 59.56M |
| December 31, 2022 | 83.75M |
| Date | Value |
|---|---|
| December 31, 2021 | 117.67M |
| December 31, 2020 | 81.79M |
| December 31, 2019 | 29.74M |
| December 31, 2018 | 9.167M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| ARS Pharmaceuticals, Inc. | 13.18M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Anika Therapeutics, Inc. | 25.77M |
| Savara, Inc. | 81.40M |